Robert A. Byrne

Robert A. Byrne

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Robert A. Byrne

Department of Cardiology and Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in European Heart Journal
Verified
Journal Article
Closed access
RBRobert A Byrne
Robert A Byrne
XRXavier Rossello
Xavier Rossello
JCJ J Coughlan
J J Coughlan
EBEmanuele Barbato
Emanuele Barbato
CBColin Berry
Colin Berry
EGESC Scientific Document Group
ESC Scientific Document Group

26 August 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MVMarco Valgimigli
Marco Valgimigli
HBHéctor Bueno
Héctor Bueno
RBRobert A Byrne
Robert A Byrne
JCJean-Philippe Collet
Jean-Philippe Collet
FCFrancesco Costa
Francesco Costa
TKTim Kinnaird
Tim Kinnaird
The disclosure forms of all experts involved in the development of this focused update are available on the ESC website http://www.escardio.org/guidelines.

26 March 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MBMarie-Luise von Brühl
Marie-Luise von Brühl
KSKonstantin Stark
Konstantin Stark
ASAlexander Steinhart
Alexander Steinhart
SCSue Chandraratne
Sue Chandraratne
IKIldiko Konrad
Ildiko Konrad
SMSteffen Massberg
Steffen Massberg
Deep vein thrombosis (DVT) is a major cause of cardiovascular death. The sequence of events that promote DVT remains obscure, largely as a result of the lack of an appropriate rodent model. We describe a novel mouse model of DVT which reproduces a frequent trigger and resembles the time course, histological features, and clinical presentation of DVT in humans. We demonstrate by intravital two-photon and epifluorescence microscopy that blood monocytes and neutrophils crawling along and adhering to the venous endothelium provide the initiating stimulus for DVT development. Using conditional mutants and bone marrow chimeras, we show that intravascular activation of the extrinsic pathway of coagulation via tissue factor (TF) derived from myeloid leukocytes causes the extensive intraluminal fibrin formation characteristic of DVT. We demonstrate that thrombus-resident neutrophils are indispensable for subsequent DVT propagation by binding factor XII (FXII) and by supporting its activation through the release of neutrophil extracellular traps (NETs). Correspondingly, neutropenia, genetic ablation of FXII, or disintegration of NETs each confers protection against DVT amplification. Platelets associate with innate immune cells via glycoprotein Ibα and contribute to DVT progression by promoting leukocyte recruitment and stimulating neutrophil-dependent coagulation. Hence, we identified a cross talk between monocytes, neutrophils, and platelets responsible for the initiation and amplification of DVT and for inducing its unique clinical features.

1 November 2008 in JACC
Verified
Journal Article
Closed access
MSMelchior Seyfarth
Melchior Seyfarth
DSDirk Sibbing
Dirk Sibbing
IBIris Bauer
Iris Bauer
GFGeorg Fröhlich
Georg Fröhlich
LBLorenz Bott-Flügel
Lorenz Bott-Flügel
ASAlbert Schömig
Albert Schömig

22 May 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LRLorenz Räber
Lorenz Räber
GMGary S Mintz
Gary S Mintz
KKKonstantinos C Koskinas
Konstantinos C Koskinas
TJThomas W Johnson
Thomas W Johnson
NHNiels R Holm
Niels R Holm
RCRickey Carter
Rickey Carter
This Consensus Document is the first of two reports summarizing the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on the clinical use of intracoronary imaging including intravascular ultrasound (IVUS) and optical coherence tomography (OCT). The first document appraises the role of intracoronary imaging to guide percutaneous coronary interventions (PCIs) in clinical practice. Current evidence regarding the impact of intracoronary imaging guidance on cardiovascular outcomes is summarized, and patients or lesions most likely to derive clinical benefit from an imaging-guided intervention are identified. The relevance of the use of IVUS or OCT prior to PCI for optimizing stent sizing (stent length and diameter) and planning the procedural strategy is discussed. Regarding post-implantation imaging, the consensus group recommends key parameters that characterize an optimal PCI result and provides cut-offs to guide corrective measures and optimize the stenting result. Moreover, routine performance of intracoronary imaging in patients with stent failure (restenosis or stent thrombosis) is recommended. Finally, strengths and limitations of IVUS and OCT for guiding PCI and assessing stent failures and areas that warrant further research are critically discussed.

28 September 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RBRobert A. Byrne
Robert A. Byrne
MJMichael Joner
Michael Joner
AKAdnan Kastrati
Adnan Kastrati
Modern-day stenting procedures leverage advances in pharmacotherapy and device innovation. Patients treated with contemporary antiplatelet agents, peri-procedural antithrombin therapy and new-generation drug-eluting stents (DES) have excellent outcomes over the short to medium term. Indeed, coupled with the reducing costs of these devices in most countries there remain very few indications where patients should be denied treatment with standard-of-care DES therapy. The two major causes of stent failure are stent thrombosis (ST) and in-stent restenosis (ISR). The incidence of both has reduced considerably in recent years. Current clinical registries and randomized trials with broad inclusion criteria show rates of ST at or <1% after 1 year and ∼0.2–0.4% per year thereafter; rates of clinical ISR are 5% respectively. Angiographic surveillance studies in large cohorts show rates of angiographic ISR of ∼10% with new-generation DES. The advent of high-resolution intracoronary imaging has shown that in many cases of late stent failure neoatherosclerotic change within the stented segment represents a final common pathway for both thrombotic and restenotic events. In future, a better understanding of the pathogenesis of this process may translate into improved late outcomes. Moreover, the predominance of non-stent-related disease as a cause of subsequent myocardial infarction during follow-up highlights the importance of lifestyle and pharmacological interventions targeted at modification of the underlying disease process. Finally, although recent developments focus on strategies which circumvent the need for chronically indwelling stents—such as drug-coated balloons or fully bioresorbable stents—more data are needed before the wider use of these therapies can be advocated.